Thyroid dysfunction in patients with type 2 diabetes mellitus


Cite item

Full Text

Abstract

The paper gives an update on type 2 diabetes mellitus concurrent with thyroid dysfunction and on the development of vascular events, atherogenesis and evaluates the impact of therapy on the course of both diseases. It points out the need for annual screening for thyroid dysfunction in patients with type 2 diabetes mellitus.

Full Text

Дисфункция щитовидной железы у больных сахарным диабетом 2-го типа. - Аннотация. Представлены современные данные о сочетании сахарного диабета 2-го типа и дисфункции щитовидной железы (ЩЖ), о развитии сосудистых осложнений, атерогенеза; оценено влияние терапии на течение обоих заболеваний. Указано на необходимость проводить ежегодное скрининговое обследование больных сахарным диабетом 2-го типа для выявления дисфункции ЩЖ.
×

About the authors

I V Tereshchenko

Email: i_v_t@bk.ru

A A Suslina

References

  1. Сахарный диабет: диагностика лечение и профилактика. Под ред. И.И. Дедова, М.В. Шестаковой. М: МИА 2012: 20.
  2. Петунина Н.А. Болезни щитовидной железы. М: ГЭОТАР-МЕД 2011: 15.
  3. Hage M., Zantout M.S., Azar S.T. Thyroid disorders and diabetes mellitus. J Thyroid Res 2011; 2011: 439-463.
  4. Chubb S.A., Davis W.A., Inman Z., Davis T.M. Prevalence and progression of subclinical hypothyroidism in women with type 2 diabetes: the Fremantle Diabetes Study. Clin Endocrinol (Oxf) 2005; 62 (4): 480-486.
  5. Smithson M.J. Screening for thyroid dysfunction in a community population of diabetic patients. Diabet Med 1998; 15 (2): 148-150.
  6. Ashrafuzzaman S.M., Taib A.N., Rahman R., Latif Z.A. Prevalence of diabetes among hypothyroid subjects. Mymensingh Med J 2012; 21 (1): 129-132.
  7. Papazafiropoulou A., Sotiropoulos A., Kokolaki A. et al. Prevalence of thyroid dysfunction among greek type 2 diabetic patients attending an outpatient clinic. J Clin Med Res 2010; 2 (2): 75-78.
  8. Ishay A., Chertok-Shaham I., Lavi I., Luboshitzky R. Prevalence of subclinical hypothyroidism in women with type 2 diabetes. Med Sci Monit 2009; 15 (4): 151-155.
  9. Radaideh A.R., Nusier M.K., Amari F.L. et al. Thyroid dysfunction in patients with type 2 diabetes mellitus in Jordan. Saudi Med J 2004; 25 (8): 1046-1050.
  10. Demitrost L., Ranabir S. Thyroid dysfunction in type 2 diabetes mellitus: A retrospective study. Indian J Endocrinol Metab 2012; 16 (Suppl 2): 334-335.
  11. Diez J.J., Iglesias P. Subclinical hyperthyroidism in patients with type 2 diabetes. Endocrine 2012; 42 (1):157-163.
  12. Yang G.R., Yang J.K., Zhang L. et al. Association between subclinical hypothyroidism and proliferative diabetic retinopathy in type 2 diabetic patients: a case-control study. Tohoku J Exp Med 2010; 222 (4): 303-310.
  13. Tamez-Perez H.E., Martínez E., Quintanilla-Flores D.L. et al. The rate of primary hypothyroidism in diabetic patients is greater than in the non-diabetic population. An observational study. Med Clin (Barc) 2012; 138 (11): 475-477.
  14. Akbar D.H., Ahmed M.M., Al-Mughales J. Thyroid dysfunction and thyroid autoimmunity in Saudi type 2 diabetics. Acta Diabetol 2006; 43: 14-18.
  15. Johnson J.L. Diabetes Control in Thyroid Disease. Diabetes Spectrum 2006; 19 (3): 148-153.
  16. Wu P. Thyroid disorders and diabetes. It is common for a person to be affected by both thyroid disease and diabetes. Diabetes Self Manag 2007; 24 (5): 80-82, 85-87.
  17. Perros P., McCrimmon R.J., Shaw G., Frier B.M. Frequency of thyroid dysfunction in diabetic patients: value of annual screening. Diabet Med 1995; 12 (7): 622-627.
  18. Shih S.R., Chiu W.Y., Chang T.C., Tseng C.H. Diabetes and thyroid cancer risk: literature review. Exp Diabetes Res 2012; 5: 782-785.
  19. Балаболкин М.И. Дифференциальная диагностика и лечение эндокринных заболеваний. М: МИА 2008: 185-193.
  20. Thvilum M., Brandt F., Brix T.H., Hegedüs L. A review of the evidence for and against increased mortality in hypothyroidism. Nat Rev Endocrinol 2012; 8 (7): 417-424.
  21. Pasqualetti G., Tognini S., Polini A. et al. Is subclinical hypothyroidism a cardiovascular risk factor in the elderly? J Clin Endocrinol Metab 2013; 98 (6): 2256-2266.
  22. Mitu F., Cojocaru E., Tamba B., Leon M.M. Prevalence of cardiovascular diseases in patients with hypothyroidism. Rev Med Chir Soc Med Nat Iasi 2012; 116 (2): 413-418.
  23. Moura Neto A., Parisi M.C., Tambascia M.A. et al. Relationship of thyroid hormone levels and cardiovascular events in patients with type 2 diabetes. Endocrine 2013 Apr 2. [Epub ahead of print]
  24. Chen H.S., Wu T.E.J., Jap T.S. et al. Subclinical hypothyroidism is a risk factor for nephropathy and cardiovascular diseases in Type 2 diabetic patients. Diabetic Med 2007; 24 (12): 1336-1344.
  25. Сазонова Е.Г., Мохорт Т.В. Тиреоидная функция при сахарном диабете, осложненном хронической болезнью почек. Междунар эндокринол журн 2013; 2: 20-23.
  26. Ramis J.N., Artigas C.F., Santiago M.A. et al. Is there a relationship between TSH levels and diabetic retinopathy in the Caucasian population? Diabetes Res Clin Pract 2012; 97 (3): 45-47.
  27. Yang J.K., Liu W., Shi J., Li Y.B. An association between subclinical hypothyroidism and sight-threatening diabetic retinopathy in type 2 diabetic patients. Diabetes Care 2010; 33 (5): 1018-1020.
  28. Valentina V.N., Marijan B., Chedo D., Branka K. Subclinical hypothyroidism and risk to carotid atherosclerosis. Arq Bras Endocrinol Metabol 2011; 55 (7): 475-480.
  29. Cappola A.R., Ladenson P.W. Hypothyroidism and atherosclerosis. J Clin Endocrinol Metab 2003; 88 (6): 2438-2444.
  30. La Vignera S., Condorelli R., Vicari E., Calogero A.E. Endothelial dysfunction and subclinical hypothyroidism: a brief review. J Endocrinol Invest 2012; 35 (1): 96-103.
  31. Ichiki T. Thyroid hormone and atherosclerosis. Vascul Pharmacol 2010; 52 (3-4): 151-156.
  32. Kutluturk F., Yuce S., Tasliyurt T. et al. Changes in metabolic and cardiovascular risk factors before and after treatment in overt hypothyroidism. Med Glas (Zenica) 2013; 10 (2): 348-353.
  33. Sigal G.A., Medeiros-Neto G., Vinagre J.C. et al. Lipid metabolism in subclinical hypothyroidism: plasma kinetics of triglyceride-rich lipoproteins and lipid transfers to high-density lipoprotein before and after levothyroxine treatment. Thyroid 2011; 21 (4): 347-353.
  34. Kowalska I., Borawski J., Nikołajuk A. et al. Insulin sensitivity, plasma adiponectin and sICAM-1 concentrations in patients with subclinical hypothyroidism: response to levothyroxine therapy. Endocrine 2011; 40 (1): 95-101.
  35. Wang C. The Relationship between Type 2 Diabetes Mellitus and Related Thyroid Diseases. J Diabetes Res 2013; 2013: 390-413.
  36. Баранов В.Г., Оркодашвили Л.Ш. Болезни островкового аппарата поджелудочной железы. В кн: Руководство по клинической эндокринологии. Под ред. В.Г. Баранова. Л: Медицина 1977: 31-136.
  37. Терещенко И.В., Трефилова Е.С. Тиреоидная патология у больных сахарным диабетом. Сахарный диабет 2001; 4: 22-24.
  38. Ittermann T., Markus M.R., Schipf S. et al. Metformin inhibits goitrogenous effects of type 2 diabetes. Eur J Endocrinol 2013; 169 (1): 9-15.
  39. Cappelli C., Rotondi M., Pirola I. et al. Thyreotropin levels in diabetic patients on metformin treatment. Eur J Endocrinol 2012; 167 (2): 261-265.
  40. Casteràs A., Zafon C., Ciudin A., Mesa J. Are Levothyroxine Requirements Lower in Thyroidectomized Diabetic Patients on Metformin Treatment? Thyroid 2013 Sep 3. [Epub ahead of print]
  41. Diez J.J., Iglesias P. Relationship between serum thyrotropin concentrations and metformin therapy in euthyroid patients with type 2 diabetes. Clin Endocrinol (Oxf) 2013; 78 (4): 505-511.
  42. Kouidhi S., Berhouma R., Ammar M. et al. Relationship of thyroid function with obesity and type 2 diabetes in euthyroid Tunisian subjects. Endocr Res 2013; 38 (1): 15-23.
  43. Kitahara C.M., Platz E.A., Freeman L.E. et al. Obesity and thyroid cancer risk among U.S. men and women: a pooled analysis of five prospective studies. Cancer Epidemiol Biomark Prevent 2011; 20 (3): 464-472.
  44. Renehan A.G., Tyson M., Egger M. et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371 (9612): 569-578.
  45. Uddin S., Bavi P., Siraj A.K. et al. Leptin-R and its association with PI3K/AKT signaling pathway in papillary thyroid carcinoma. Endocrine-Related Cancer 2010; 17 (1): 191-202.
  46. Currie C.J., Poole C.D., Gale E.A. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52 (9): 1766-1777.
  47. Chen G., Xu S., Renko K., Derwahl M. Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. J Clin Endocrinol Metab 2012; 97 (4): 510-520.
  48. Klubo-Gwiezdzinska J., Costello J.Jr., Patel A. et al. Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer. J Clin Endocrinol Metab 2013; 98 (8): 3269-3279.
  49. Currie C.J., Poole C.D., Gale E.A. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52 (9): 1766-1777.
  50. Tahrani A.A., Ball A., Shepherd L. et al. The prevalence of vitamin D abnormalities in South Asians with type 2 diabetes mellitus in the UK. Intern J Clin Pract 2010; 64 (3): 351-355.
  51. Aschebrook-Kilfoy B., Sabra M.M., Brenner A. et al. Diabetes and thyroid cancer risk in the National Institutes of Health-AARP Diet and Health study. Thyroid 2011; 21 (9): 957-963.
  52. Knudsen L.B., Madsen L.W., Andersen S. et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010; 151 (4): 1473-1486.
  53. Madsen L.W., Knauf J.A., Gotfredsen C. et al. GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. Endocrinology 2012; 153 (3): 1538-1547.
  54. Gallo M. Thyroid safety in patients treated with liraglutide. J Endocrinol Invest 2013; 36 (2): 140-145.
  55. Drucker D.J., Sherman S.I., Bergenstal R.M., Buse J.B. The safety of incretin-based therapies-review of the scientific evidence. J Clin Endocrinol Metab 2011; 96 (7): 2027-2031.
  56. Handelsman Y., Leroith D., Bloomgarden Z.T. et al. Diabetes and Cancer - an AACE/ACE Consensus statement. Endocr Pract 2013; 19 (4): 675-693.
  57. Melville N.A. Hypothyroidism Shows Strong Association with Type 2 Diabetes, Screening Recommended. American Association of Clin. Endocrinologists (AACE) www.docguide.com/hypothyroidism-shows-strong-association-type-2-diabetes-screening-recommended
  58. Kadiyala R., Peter R., Okosieme O.E. Thyroid dysfunction in patients with diabetes: clinical implications and screening strategies. Int J Clin Pract 2010; 64 (8): 1130-1139.

Copyright (c) 2014 Tereshchenko I.V., Suslina A.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies